Todd Golub is a founding core member of the Broad Institute and serves as the institute's chief scientific officer and director of its Cancer Program.
Golub is a world leader in understanding the basis of cancer, by creating and applying tools of genomics. He has made fundamental discoveries in the molecular basis of childhood leukemia, and laid the foundation for the diagnosis and classification of human cancers using gene expression analysis. He also pioneered the development of chemical screening approaches based on gene expression.
He joined the faculty of the Dana-Farber Cancer Institute and Harvard Medical School in 1997. At the same time he served as the leader of cancer genomics at the Whitehead Institute/MIT Center for Genome Research, which evolved into the Cancer Program at the Broad Institute, which he has directed since 2004. Golub is currently the Charles A. Dana Investigator in Human Cancer Genetics at the Dana-Farber Cancer Institute, professor of pediatrics at Harvard Medical School, and a Howard Hughes Medical Institute investigator.
He is the recipient of multiple awards, including the Erasmus Hematology Award, the Richard and Hinda Rosenthal Memorial Award and the Outstanding Achievement Award from the American Association for Cancer Research, the Paul Marks Prize for Cancer Research, the E. Mead Johnson Award from the Society for Pediatric Research, and the Judson Daland Prize for Outstanding Achievement in Clinical Investigation from the American Philosophical Society.
Golub serves on the Board of Directors of the Damon Runyon Cancer Research Foundation and the American Association for Cancer Research. He also serves on the scientific advisory boards of the Sanford-Burnham Medical Research Institute, the Wistar Institute, and St. Jude Children’s Research Hospital. He also serves as Chair of the Board of Scientific Advisors of the National Cancer Institute (effective 11/11).
Golub received his B.A. from Carleton College and his M.D. from the University of Chicago Pritzker School of Medicine. He completed his internship, residency, and fellowship training at Children’s Hospital Boston and the Dana-Farber Cancer Institute.